Oncohematología y Genética

Inmunoterapia del cáncer

Luis de la Cruz Merino
Luis de la Cruz Merino

Luis de la Cruz Merino

Volver al programa
  1. Miembros del grupo
  2. Áreas de trabajo
  3. Publicaciones

Grupo: Inmunoterapia del cáncer

Directorio
Foto no disponible
  • de la Cruz Merino, Luis.Doctor en Medicina
  • García Domínguez, Daniel José.Doctor en Biología
  • Sánchez Margalet, Victor.

Áreas de trabajo

Revistas Internacionales
Majem, M; Garcia-Martinez, E; Martinez, M; Munoz-Couselo, E; Rodriguez-Abreu, D; Alvarez, R; Arance, A; Berrocal, A; de la Cruz-Merino, L; Lopez-Martin, JA
SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)
CLINICAL & TRANSLATIONAL ONCOLOGY
Perez-Ruiz, E; Jimenez-Castro, J; Berciano-Guerrero, MA; Valdivia, J; Estalella-Mendoza, S; Toscano, F; Artacho, MRD; Garrido-Siles, M; Martinez-Bautista, MJ; Roldan, RV; Rivas-Ruiz, F; Nogales-Fernandez, E; Morales, C; Perez-Valderrama, B; De la Cruz-Merino, L; Rueda, A
Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice
CLINICAL & TRANSLATIONAL ONCOLOGY
Ascierto, PA; Del Vecchio, M; Mandala, M; Gogas, H; Arance, AM; Dalle, S; Cowey, CL; Schenker, M; Grob, JJ; Chiarion-Sileni, V; Marquez-Rodas, I; Butler, MO; Maio, M; Middleton, MR; de la Cruz-Merino, L; Arenberger, P; Atkinson, V; Hill, A; Fecher, LA; Millward, M; Khushalani, NI; Queirolo, P; Lobo, M; de Pril, V; Loffredo, J; Larkin, J; Weber, J
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
LANCET ONCOLOGY
Slamon, DJ; Neven, P; Chia, S; Fasching, PA; De Laurentiis, M; Im, SA; Petrakova, K; Bianchi, GV; Esteva, FJ; Martin, M; Nusch, A; Sonke, GS; De la Cruz-Merino, L; Beck, JT; Pivot, X; Sondhi, M; Wang, YB; Chakravartty, A; Rodriguez-Lorenc, K; Taran, T; Jerusalem, G
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
NEW ENGLAND JOURNAL OF MEDICINE
Garcia, FJV; Carrion, NP; de la Cruz-Merino, L
Long-term complete response to intrathecal trastuzumab in a patient with leptomeningeal carcinomatosis due to her2-overexpressing breast cancer Case report
MEDICINE
Martin, M; Guerrero-Zotano, A; Montero, A; Jara, C; Filipovich, E; Rojo, F; Moreno, F; Garcia-Saenz, JA; Ales, JE; Chacon, JI; Cruz, J; Gimenez, J; Cruz-Merino, L; Algara, M; Santisteban, M; Tarruella, SL
GEICAMGuidelines for the Management of Patients with Breast Cancer During theCOVID-19 Pandemic in Spain
ONCOLOGIST
Sanegre, S; Lucantoni, F; Burgos-Panadero, R; de La Cruz-merino, L; Noguera, R; Naranjo, TA
Integrating the Tumor Microenvironment into Cancer Therapy
CANCERS
Pascual, T; Cejalvo, JM; Oliveira, M; Vidal, M; Vega, E; Ganau, S; Julve, A; Zamora, E; Miranda, I; Delgado, A; Bermejo, B; de la Cruz- Merino, L; Juan, M; Ferrero-Cafiero, JM; Canes, J; Gonzalez, X; Villagrasa, P; Prat, A
SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer
FUTURE ONCOLOGY
Kandolf Sekulovic L, Guo J, Agarwala S, Hauschild A, McArthur G, Cinat G, Wainstein A, Caglevic C, Lorigan P, Gogas H, Álvarez M, Duncombe R, Lebbe C, Peris K, Rutkowski P, Stratigos A, Forsea AM, De La Cruz Merino L, Kukushkina M, Dummer R, Hoeller C, Gorry C, Bastholt L, Herceg D, Neyns B, Vieira R, Arenberger P, Bylaite-Bucinskiene M, Babovic N, Banjin M, Putnik K, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Ymeri A, Stojkovski I, Garbe C.
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.
Eur J Cancer
Losa F, Iglesias L, Pané M, Sanz J, Nieto B, Fusté V, de la Cruz-Merino L, Concha Á, Balañá C, Matías-Guiu X.
2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary.
Clin Transl Oncol.
Rueda A, Calvo V, Casanova M, Rodríguez-Abreu D, Aguiar D, Llanos M, Álvarez R, Martínez-Banaclocha N, Alfaro J, Quero C, Blasco A, de la Cruz Merino L, Herrero J, García-Arroyo FR, Provencio M.
Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group.
Leuk Lymphoma.
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodríguez Lorenc K, Miller M, Taran T, Jerusalem G.
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
J Clin Oncol.
Yardley DA, Coleman R, Conte P, Cortes J, Brufsky A, Shtivelband M, Young R, Bengala C, Ali H, Eakel J, Schneeweiss A, de la Cruz-Merino L, Wilks S, O'Shaughnessy J, Glück S, Li H, Miller J, Barton D, Harbeck N, tnAcity investigators.
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
Ann Oncol.